Lantheus Holdings Inc (LNTH) Director Brian A. Markison Sells 5,000 Shares

Share on StockTwits

Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.73, for a total value of $123,650.00. Following the completion of the transaction, the director now owns 62,467 shares in the company, valued at approximately $1,544,808.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Lantheus stock opened at $24.73 on Monday. Lantheus Holdings Inc has a fifty-two week low of $12.59 and a fifty-two week high of $26.40. The firm has a market cap of $960.02 million, a price-to-earnings ratio of 26.31, a price-to-earnings-growth ratio of 1.86 and a beta of 1.52. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The company had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. Analysts expect that Lantheus Holdings Inc will post 1.11 earnings per share for the current fiscal year.

Several brokerages have recently commented on LNTH. TheStreet raised Lantheus from a “c+” rating to a “b” rating in a research note on Monday, March 4th. Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. Finally, BidaskClub lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $23.33.

Several hedge funds have recently added to or reduced their stakes in LNTH. Bank of New York Mellon Corp increased its holdings in shares of Lantheus by 19.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 442,531 shares of the medical equipment provider’s stock worth $6,616,000 after buying an additional 70,944 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in shares of Lantheus by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 28,342 shares of the medical equipment provider’s stock worth $424,000 after buying an additional 10,075 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Lantheus by 32.7% during the 3rd quarter. Legal & General Group Plc now owns 81,682 shares of the medical equipment provider’s stock worth $1,209,000 after buying an additional 20,131 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Lantheus by 14.0% during the 4th quarter. State of Alaska Department of Revenue now owns 12,881 shares of the medical equipment provider’s stock worth $201,000 after buying an additional 1,580 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Lantheus by 7.0% during the 4th quarter. Bank of Montreal Can now owns 228,227 shares of the medical equipment provider’s stock worth $3,572,000 after buying an additional 14,847 shares during the last quarter. Institutional investors and hedge funds own 92.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Lantheus Holdings Inc (LNTH) Director Brian A. Markison Sells 5,000 Shares” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4354018/lantheus-holdings-inc-lnth-director-brian-a-markison-sells-5000-shares.html.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report